TECHNOLOGYAttenuated Strains of SalmonellaTyphi as Mucosal Live Typhoid Vaccines and Expression Vectors
Overview
Salmonella enterica serovar Typhi is the cause of typhoid fever, which remains an important public health problem in many parts of the world. Attenuated strains of S. Typhi were engineered by researchers at UMB's Center for Vaccine Development, and selected strains have proven safe and immunogenic in Phase 1 and Phase 2 human trials. The same strains have proven to be excellent live vectors for the expression of foreign antigens, making these strains very versatile for vaccine development.
Applications
Active immunization against typhoid fever in high risk populations. Also proven as an oral delivery system as basis for vaccines against multiple types of pathogens.
Advantages
More convenient (i.e. one-dose, oral) vaccine against typhoid fever than currently available commercial vaccines. A need remains for improved typhoid fever vaccines, as the currently available commercial vaccines are only moderately effective (50% to 70%).
Stage of Development
The vaccine strain CVD 909 is in Phase 2 clinical development, having completed a second Phase 1 trial in a prime-boost regimen with the live strain CVD 909 as an oral prime followed by a parenteral boost with commercial Vi polysaccharide vaccine.
R&D Required
Completion of clinical testing.
Licensing Potential
UMB seeks partners for completion of clinical development.
Contact Info
Office of Technology Transfer
620 W Lexington St., 4th Floor
Baltimore, MD 21201
Email: [email protected]
Phone: (410) 706-2380